Excessive epidermal growth factor receptor (EGF-R) signaling is linked to multiple cancers. Understanding the mechanisms of action of endogenous EGF-R suppressors may lead to novel antitumor therapies. The E3/ubiquitin ligase Cbl is an endogenous EGF-R signaling suppressor that enhances EGF-R ubiquitination, downregulation and lysosomal degradation. Cbl also mediates the degradation of the endocytic trafficking regulators Sprouty2 and Hrs. All of these functions depend upon the integrity of a Cbl domain known as the RING finger (RF) tail. We have noted sequence similarity between the Cbl and Mdm2 RF tails. The Cbl- related RF tail residues of Mdm2 enhance Mdm2's oligomerization and E3 activity. Here, we hypothesize that Cbl's RF tail regulates Sprouty2, Hrs, and EGF-R fate by enhancing their ubiquitination via Cbl oligomerization. Furthermore, we postulate that RF tail-dependent phosphorylation of Hrs is necessary for efficient Hrs and EGF-R degradation. Finally, we propose that RF tail-dependent Hrs phosphorylation alters endosome fusion activity or the composition of endosomal sorting machinery/EGF-R complexes, thereby altering the degradative trafficking of EGF-R.
Aim I : wild type and RF tail mutant Cbl proteins will be compared in vitro for their ability to: a) form and maintain Cbl oligomers;b) interact with the E2 protein UbcH7;and c) enhance target protein ubiquitination. Structure-function studies in a cellular context will test whether Cbl residues that may interact with the RF tail at oligomer interfaces are functionally important for Sprouty2 and EGF-R ubiquitination/ degradation. Finally, wt Cbl and RF tail/other Cbl mutants will be compared for their impact on receptor trafficking and signaling.
Aim II : Cbl mutants and an shRNA Hrs knockdown/reconstitution approach will be used to test the hypothesis that Hrs tyrosine phosphorylation controls EGF-R signaling, trafficking, and degradation.
Aim III : wt and mutant Hrs proteins will be used to test specific mechanisms through which Hrs tyrosine phosphorylation sites may regulate EGF-R fate, including the modulation of endosome fusion and protein-protein interactions. Overexpression of EGF receptors is associated with a variety of tumors of epithelial origin, including those of the breast, pancreas, colon, bladder, prostate, head and neck, and lung. The study of endogenous suppressors of EGF-R signaling could reveal novel molecular targets for therapeutic intervention in these cancers. For this reason, defining how Cbl and Hrs interact to regulate EGF-R signaling and degradation is an important goal in cancer research.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Membrane Biology and Protein Processing (MBPP)
Program Officer
Salnikow, Konstantin
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Ohio State University
Schools of Medicine
United States
Zip Code
Krager, Kimberly J; Sarkar, Mitul; Twait, Erik C et al. (2012) A novel biotinylated lipid raft reporter for electron microscopic imaging of plasma membrane microdomains. J Lipid Res 53:2214-25
Lill, Nancy L; Sever, Nurettin Ilter (2012) Where EGF receptors transmit their signals. Sci Signal 5:pe41
Visser Smit, Gina D; Place, Trenton L; Cole, Sara L et al. (2009) Cbl controls EGFR fate by regulating early endosome fusion. Sci Signal 2:ra86
Stern, Kathryn A; Place, Trenton L; Lill, Nancy L (2008) EGF and amphiregulin differentially regulate Cbl recruitment to endosomes and EGF receptor fate. Biochem J 410:585-94